The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancerDale W. Garsed, David D.L. Bowtell, Ahwan Pandey et al.|Nature Genetics|2022Cited by 115
Going to extremes: determinants of extraordinary response and survival in patients with cancerFlurina A.M. Saner, David D.L. Bowtell, Alan Herschtal et al.|Nature reviews. Cancer|2019Cited by 51
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaFlurina A.M. Saner, Jennifer M. Koziak, Laura Twomey et al.|Clinical Cancer Research|2024Cited by 14
Concurrent RB1 loss and <i>BRCA</i> -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaFlurina A.M. Saner, Jennifer M. Koziak, Kazuaki Takahashi et al.|medRxiv|2023Cited by 5